Fragile Drugs, Broken Cold Chains

Biological therapeutics — cell therapies, vaccines, blood products, tissue grafts, mRNA drugs — require continuous cold chain storage (2–8°C for most vaccines, -20°C for some biologics, -80°C for mRNA, and liquid nitrogen temperatures for cell therapies) from manufacture to administration. Cold chain infrastructure is expensive, energy-intensive, fragile, and unavailable in many low-resource settings. An estimated 25% of vaccines reach patients degraded due to cold chain failures, and cell therapies (CAR-T, stem cell products) have a viability window of 24–72 hours even under optimal cold chain conditions. No technology exists to stabilize living cells or complex biologics at room temperature while maintaining their function, because the mechanisms that protect organisms from desiccation and heat stress (trehalose accumulation, heat shock proteins, late embryogenesis abundant proteins) are not well enough understood to be replicated in therapeutic products.

The global cold chain logistics market for pharmaceuticals exceeds $18 billion annually and is growing 8% per year. Cold chain failures waste an estimated $35 billion in pharmaceutical products annually worldwide. In sub-Saharan Africa, only 10% of health facilities have reliable cold chain for vaccine storage. COVID-19 exposed the cold chain bottleneck acutely: mRNA vaccines requiring -80°C storage could not reach rural and low-resource communities for months after becoming available. Cell therapies, which must be manufactured and administered within a tight viability window, are limited to major medical centers near manufacturing facilities. Room-temperature stabilization would democratize access to biologics globally and reduce waste, cost, and environmental impact.

Lyophilization (freeze-drying) works for some protein-based biologics and vaccines but destroys living cells — the ice crystal formation during freezing ruptures cell membranes. Adding cryoprotectants (DMSO, glycerol, trehalose) can protect cells during freezing but requires rapid thawing at the point of use and does not extend shelf life at room temperature. Anhydrobiosis research (studying organisms like tardigrades and brine shrimp that survive complete desiccation) has identified protective molecules, but introducing these into mammalian cells without disrupting cell function is an unsolved challenge. Encapsulation in alginate or other hydrogels can protect cells for hours but not the weeks to months needed for storage and distribution. For mRNA therapeutics, lipid nanoparticle encapsulation provides some thermal stability but still requires -20°C or lower for multi-month shelf life.

Technologies that enable room-temperature storage of living cells for weeks to months while maintaining viability and function would transform biologics access. Approaches include: (1) engineering mammalian cells to express natural desiccation tolerance pathways (trehalose synthesis, LEA protein production) that enable them to survive dehydration; (2) novel encapsulation matrices that physically immobilize cells in a glass-like state at room temperature while maintaining membrane integrity; (3) synthetic analogs of natural cryoprotectants that can be loaded into cells at non-toxic concentrations. Success metrics are clear: >80% cell viability after 30+ days at 25°C, with retention of therapeutic function.

A student team could engineer a mammalian cell line to express trehalose synthase (from E. coli or tardigrade orthologs) and measure whether intracellular trehalose accumulation improves survival after controlled desiccation and rehydration. A materials-focused team could screen different hydrogel and sugar-glass encapsulation matrices for their ability to maintain red blood cell integrity at room temperature over days to weeks. Relevant disciplines: biomedical engineering, cell biology, materials science, chemical engineering.